CEL-SCI Corporation CVM today announced that it has signed a
co-development and profit sharing agreement with Ergomed Clinical Research
Ltd. for CEL-SCI's investigational immunotherapy drug Multikine (“Leucocyte
Interleukin Inj.”) in HIV/HPV co-infected women with cervical dysplasia. Human
Papilloma Virus (HPV) is the most common sexually transmitted disease. HPV is
a significant health problem in the HIV infected population as individuals are
living longer as a result of greatly improved HIV medications. People living
with HIV and others with compromised immunity are more at risk for HPV-related
complications. Persistent HPV infection can also be a precursor to cervical
cancer.
Under the terms of this agreement, Ergomed will assume 50% (up to $3 million)
of the clinical and regulatory costs for the development of Multikine as a
potential treatment for HIV/HPV co-infected women with cervical dysplasia. The
full co-development program for Multikine must be jointly agreed to prior to
implementation. Ergomed already has a similar co-development agreement for up
to $10 million with CEL-SCI for the ongoing head and neck cancer Phase III
clinical trial. Ergomed will receive its return on investment based on an
agreed single digit percentage of any net income received by CEL-SCI for
Multikine from sales in this and the head and neck cancer indications.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in